Search results for Cixutumumab
Cixutumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade, ProteoGenix, PX-TA1205
Description of Cixutumumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade Introduction to Cixutumumab Biosimilar – A Promising Antibody for Targeting IGF1R Cixutumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb – Research Grade, is a monoclonal antibody that has shown great potential in the field of cancer therapy. This biosimilar is designed to target the insulin-like growth factor-1 receptor (IGF1R), a protein that plays a crucial role in cell growth and survival. In this article, we will discuss the structure, activity, and potential applications of Cixutumumab Biosimilar. Structure of Cixutumumab Biosimilar Cixutumumab Biosimilar is a humanized IgG1 monoclonal antibody, which means that it is derived from human antibodies and has been modified to reduce potential immune reactions in patients. The antibody is composed of two heavy chains and two light chains, connected by disulfide bonds. It has a molecular weight of approximately 150 kDa. Activity of Cixutumumab Biosimilar Cixutumumab Biosimilar specifically targets the IGF1R, a transmembrane receptor that is expressed on the surface of many types of cancer cells. This receptor is activated by the binding of insulin-like growth factors (IGF) and plays a crucial role in promoting cell growth and survival. Overexpression of IGF1R has been linked to the development and progression of various types of cancer, making it a promising therapeutic target. By binding to IGF1R, Cixutumumab Biosimilar inhibits the binding of IGF and blocks the downstream signaling pathways that promote cancer cell growth and survival. This leads to the inhibition of tumor growth and ultimately, cancer cell death. Additionally, Cixutumumab Biosimilar has been shown to enhance the activity of other cancer treatments, such as chemotherapy and radiation therapy, making it a potential combination therapy for cancer treatment. Potential Applications of Cixutumumab Biosimilar Cixutumumab Biosimilar is currently being studied in clinical trials for the treatment of various types of cancer, including lung, breast, and prostate cancer. Preliminary results have shown promising anti-tumor activity, with some patients experiencing tumor shrinkage and prolonged survival. It is also being investigated as a potential treatment for pediatric cancers, such as Ewing’s sarcoma and neuroblastoma. In addition to its potential as a standalone therapy, Cixutumumab Biosimilar is also being studied in combination with other cancer treatments. Preclinical studies have shown that combining Cixutumumab Biosimilar with chemotherapy or radiation therapy can enhance their anti-tumor effects, making it a potential adjuvant therapy for cancer treatment. Conclusion Cixutumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb – Research Grade, is a promising antibody that specifically targets the insulin-like growth factor-1 receptor (IGF1R). Its unique structure and mechanism of action make it a potential therapy for various types of cancer. As further research and clinical trials are conducted, Cixutumumab Biosimilar has the potential to become a valuable addition to the arsenal of treatments for cancer patients.
Host
Reactivity
Applications
Conjugation
Cixutumumab, Abbexa, abx831162
Cixutumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1R/CD221, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Cixutumumab ELISA Kit, ProteoGenix, KPTX157
Description of Cixutumumab ELISA Kit Introduction Cixutumumab is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). It has been shown to have potential therapeutic effects in various types of cancer, such as lung, breast, and sarcoma. In order to accurately measure the levels of Cixutumumab in biological samples, a specialized enzyme-linked immunosorbent assay (ELISA) kit has been developed. In this article, we will discuss the structure, activity, and applications of the Cixutumumab ELISA Kit. Structure of Cixutumumab ELISA Kit The Cixutumumab ELISA Kit is a commercially available kit that contains all the necessary components for the quantitative measurement of Cixutumumab in various biological samples. The kit consists of a 96-well plate pre-coated with a specific antibody against Cixutumumab, a standard solution of known concentration, and all the reagents needed for the assay. The kit also includes a detection antibody and a substrate solution for the colorimetric detection of Cixutumumab. Activity of Cixutumumab ELISA Kit The Cixutumumab ELISA Kit utilizes the principle of sandwich ELISA for the quantitative measurement of Cixutumumab. The pre-coated antibody on the 96-well plate captures Cixutumumab present in the sample. The detection antibody, which is specific to a different epitope on Cixutumumab, is then added and binds to the captured Cixutumumab. This forms a sandwich complex, which is then detected using a colorimetric substrate. The intensity of the color is directly proportional to the amount of Cixutumumab present in the sample. Applications of Cixutumumab ELISA Kit The Cixutumumab ELISA Kit has several applications in the field of cancer research and drug development. Some of the key applications are: 1. Quantification of Cixutumumab levels in biological samples The primary use of the Cixutumumab ELISA Kit is for the accurate measurement of Cixutumumab levels in various biological samples, such as serum, plasma, and tissue lysates. This is useful for monitoring the effectiveness of Cixutumumab treatment in cancer patients and for studying the pharmacokinetics of the drug. 2. Screening of potential therapeutic targets The Cixutumumab ELISA Kit can also be used for screening potential therapeutic targets in cancer. By measuring the levels of Cixutumumab in different cancer cell lines, researchers can identify cell lines that are sensitive or resistant to Cixutumumab treatment. This information can then be used to identify new targets for drug development. 3. Evaluation of drug efficacy The Cixutumumab ELISA Kit can also be used to evaluate the efficacy of Cixutumumab in combination with other drugs. By measuring the levels of Cixutumumab in samples from patients receiving combination therapy, researchers can determine the effectiveness of the treatment and make necessary adjustments. 4. Biomarker discovery Cixutumumab has been shown to have potential in various types of cancer, but its effectiveness may vary depending on the type and stage of cancer. The Cixutumumab ELISA Kit can be used to measure the levels of Cixutumumab in different types of cancer, which can help identify potential biomarkers for predicting response to treatment. Conclusion In conclusion, the Cixutumumab ELISA Kit is a valuable tool for the accurate measurement of Cixutumumab levels in various biological samples. Its use in cancer research and drug development has the potential to improve our understanding of the role of Cixutumum
Host
Reactivity
Applications
Conjugation
Cixutumumab ELISA Kit, Abbexa, abx395046
Cixutumumab ELISA Kit is a quantitative ELISA kit for detection of Cixutumumab.Cixutumumab (IMC-A12) is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity for the treatment of solid tumors. This drug was developed by ImClone Systems, since acquired by Eli Lilly, using phage display technology from Dyax. Cixutumumab was well tolerated when used alone and in combination therapies, but its antitumor activity was low in the existing phase II clinical trials. An acceptable incidence of adverse effects supports further investigation of this drug, provided that it shows antitumor activity in combination with other drugs. Now, cixutumumab is involved in two cancer clinical trials, including esophageal cancer and breast cancer.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Cixutumumab Biosimilar - Research Grade, ichor.bio, ICH5144
Detects human IGF1R
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.